Avanir Pharmaceuticals is conducting a phase II, double-blind, randomized, placebo-controlled, study to assess the safety and effectiveness of three dose levels of AVP-923 (dextromethorphan/quinidine) in the treatment of central neuropathic pain in people with MS.
You may be a potential candidate for this study because you:
- Have been diagnosed with MS
- Are suffering from nerve (neuropathic) pain, (e.g. burning, pricking, numbness)
- Are between the ages of 18 – 85
If you choose to join the study, your participation will last up to 17 weeks. During this time, you will visit our office for approximately 7 visits where you will undergo various assessments and receive study-related physical examinations.
Study participants will also receive, at no charge, study related:
- Laboratory work
- Investigational medication
- Medical evaluations
Financial compensation for study related expenses will also be provided.
As with all investigational medications, there are potential risks which we will discuss fully with you and your family ahead of time.
Principal Investigator: Heidi Crayton, MD, MS Center of Greater Washington, Vienna, VA
Contact Information: To find out more about this research study and learn if you may qualify to participate, contact Christina Magnotti at (703) 226-4030 or email@example.com.
For more information on this trial visit http://clinicaltrials.gov/ct2/show/NCT01324232